Antitumour Compounds
Publication number: US2009030068 (A1)
Publication date: 2009-01-29
Inventor(s): MARTIN LOPEZ MA JESUS [ES]; REYES BENITEZ JOSE FERNANDO [ES]; FERNANDEZ RODRIGUEZ ROGELIO [ES]; FRANCESCH SOLLOSO ANDRES [ES]; CUEVAS MARCHANTE MARIA DEL CARMEN [ES]; COELLO MOLINERO LAURA [ES]
Applicant(s): PHARMA MAR SA [ES]
Classification:
- international: A61K31/335; A61P35/00; C07D323/00; A61K31/335; A61P35/00; C07D323/00
- European: C07D493/18; C07D493/18
Application number: US20060097212 20061214
Priority number(s): ES20050003092 20051215; WO2006ES00687 20061214
View INPADOC patent family
View list of citing documents
Abstract of US 2009030068 (A1)
The invention relates to novel antitumor compounds of general formula as well as their corresponding pharmaceutically acceptable salts, derivatives, prodrugs and stereoisomers. These compounds can be obtained by isolating a sponge from family Theonellidae, genus Theonella and species swinhoei, and forming derivatives from the isolated compounds. These compounds have cytotoxic activity and can be used for the treatment of the cancer.
ZAI LIMITED Y AMGEN HAN COMUNICADO HOY UN ACUERDO DE COLABORACIÓN GLOBAL DE I+D PARA EVALUAR LA COMBINACIÓN ENTRE EL ANTICUERPO CONJUGADO ZOCILURTAUG PELITECAN EN COMBINACIÓN CON TARLATAMAB ( TERAPIA BITE ) PARA EL TRATAMIENTO SMALL CELL LUNG CANCER EXTENSIVE-STAGE .///. NUEVA ESPERANZA PARA LOS PACIENTES Y POSIBLE NUEVO TRATAMIENTO ESTÁNDAR TERAPÉUTICO SMALL CELL LUNG CANCER EXTENSIVE-STAGE .

